Table 4.
Best response, n (%) | |
CR | 0 |
PR | 12 (24) |
SD, ≥ 24 weeks | 18 (35) |
SD, < 24 weeks | 14 (27) |
PD | 6 (12) |
NE | 1 (2) |
ORR | 24 % (95 %CI 12.8, 37.5) |
CBR | 59 % (95 %CI 44.2, 72.4) |
CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable, ORR overall response rate, CBR clinical benefit rate (CR; PR; SD ≥ 24 weeks)